These findings provided a powerful scientific rationale for investigating GLP-1RAs as a potential therapy for neurological diseases such as stroke
Reconstitution of Retatrutide: Why This Should Only Occur in a Regulated Clinical Setting Retatrutide has no approved SmPC, so no authoritative reconstitution guidance exists
Who GLP-1 weight loss is for - and who it isn't Patients we typically work with on GLP-1 weight management: Adults with BMI 30+ (obesity) who have not achieved sustained weight loss with lifestyle change alone Adults with BMI 27+ and weight-related comorbidities - type 2 diabetes, hypertension, dyslipidemia, sleep apnea, prediabetes, fatty liver disease Patients with insulin resistance or metabolic syndrome where the metabolic and weight pictures are intertwined Patients post-bariatric surgery with weight regain, where appropriate and coordinated with their surgical team GLP-1 medications are not appropriate for patients with personal or family history of medullary thyroid carcinoma, MEN2 syndrome, history of pancreatitis, severe gastroparesis, or active eating disorders
"Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone." J Clin Endocrinol Metab
"The way I feel today, it isn't about the weight loss," she wrote
This reduces dependence on imported components and supports supply stability at scale
